Positive rate and high positive rate of PGK1 in the malignant tumor group (96.11% and 81.55%, respectively) were significantly higher than in the borderline tumor group (57.14% and 35.71%, respectively), benign tumor group (38.46% and 23.08%, respectively), and normal ovary group (20.00% and 10.00%, respectively). Here, PGK1 is linked to cancer.